Drug Type Small molecule drug |
Synonyms PPAR ligand (Glaxo Wellcome), GW-2331, GW2331 |
Target |
Action agonists |
Mechanism PPARα agonists(Peroxisome proliferator-activated receptor α agonists), PPARγ agonists(Peroxisome proliferator-activated receptor γ agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC27H36F2N2O4 |
InChIKeyVGSJXSLGVQINOL-UHFFFAOYSA-N |
CAS Registry190844-95-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atherosclerosis | Preclinical | United States | 29 Apr 1997 | |
Diabetes Mellitus, Type 2 | Preclinical | United States | 29 Apr 1997 | |
Obesity | Preclinical | United States | 29 Apr 1997 |